Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Símbolo de cotizaciónSEER
Nombre de la empresaSeer Inc
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoFarokhzad (Omid C)
Número de empleados134
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 04
Dirección3800 Bridge Parkway, Suite 102
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94065
Teléfono16504530000
Sitio Webhttps://seer.bio/
Símbolo de cotizaciónSEER
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoFarokhzad (Omid C)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos